September 01, 1996; 47 (3) ARTICLES
A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease
L. J. Thal, A. Carta, W. R. Clarke, S. H. Ferris, R. P. Friedland, R. C. Petersen, J. W. Pettegrew, E. Pfeiffer, M. A. Raskind, M. Sano, M. H. Tuszynski, R. F. Woolson
First published September 1, 1996, DOI: https://doi.org/10.1212/WNL.47.3.705
L. J. Thal
MD
A. Carta
MD
W. R. Clarke
PhD
S. H. Ferris
PhD
R. P. Friedland
MD
R. C. Petersen
MD, PhD
J. W. Pettegrew
MD
E. Pfeiffer
MD
M. A. Raskind
MD
M. Sano
PhD
M. H. Tuszynski
MD, PhD
A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease
L. J. Thal, A. Carta, W. R. Clarke, S. H. Ferris, R. P. Friedland, R. C. Petersen, J. W. Pettegrew, E. Pfeiffer, M. A. Raskind, M. Sano, M. H. Tuszynski, R. F. Woolson
Neurology Sep 1996, 47 (3) 705-711; DOI: 10.1212/WNL.47.3.705
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 47 no. 3 705-711
PubMed:
Print ISSN:
Online ISSN:
History:
- First Published September 1, 1996.
Copyright & Usage:
Copyright 1996 by Advanstar Communications Inc.
Author Disclosures
- L. J. Thal, MD,
- A. Carta, MD,
- W. R. Clarke, PhD,
- S. H. Ferris, PhD,
- R. P. Friedland, MD,
- R. C. Petersen, MD, PhD,
- J. W. Pettegrew, MD,
- E. Pfeiffer, MD,
- M. A. Raskind, MD,
- M. Sano, PhD,
- M. H. Tuszynski, MD, PhD and
- R. F. Woolson, PhD
- L. J. Thal, MD,
- A. Carta, MD,
- W. R. Clarke, PhD,
- S. H. Ferris, PhD,
- R. P. Friedland, MD,
- R. C. Petersen, MD, PhD,
- J. W. Pettegrew, MD,
- E. Pfeiffer, MD,
- M. A. Raskind, MD,
- M. Sano, PhD,
- M. H. Tuszynski, MD, PhD and
- R. F. Woolson, PhD
- From the Department of Neurosciences (Drs. Thal and Tuszynski), University of California San Diego, La Jolla, and San Diego VAMC, San Diego, CA; Department of Neurological Research (Dr. Carta), Sigma Tau Pharmaceuticals, Rome, Italy; Division of Biostatistics (Drs. Clarke and Woolson), University of Iowa, Iowa City, IA; Department of Psychiatry (Dr. Ferris), New York University Medical Center, New York, NY; Alzheimer Center (Dr. Friedland), University Hospitals of Cleveland, Cleveland, OH; Mayo Clinic (Dr. Petersen), Rochester, MN; Department of Psychiatry (Dr. Pettegrew), University of Pittsburgh, Pittsburgh, PA; Suncoast Gerontology Center (Dr. Pfeiffer), University South Florida Health Sciences Center, Tampa, FL; Department of Psychiatry (Dr. Raskind), University of Washington, Seattle, WA; and Department of Neurology (Dr. Sano), Columbia University, New York, NY.
- Supported by Sigma Tau Pharmaceuticals, Inc.
- Received July 18, 1995. Accepted in final form February 28, 1996.
- Address correspondence and reprint requests to Dr. Leon J. Thal, Department of Neurosciences (0624), UCSD School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0624.
Article usage
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Metrifonate treatment of the cognitive deficits of Alzheimer's diseaseJ. L. Cummings, P. A. Cyrus, F. Bieber et al.Neurology, May 01, 1998 -
Articles
Idebenone treatment fails to slow cognitive decline in Alzheimer’s diseaseL. J. Thal, M. Grundman, J. Berg et al.Neurology, December 08, 2003 -
Articles
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer diseaseM. Sano, K.L. Bell, D. Galasko et al.Neurology, July 27, 2011 -
Articles
Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's diseaseJohn C. Morris, Pamela A. Cyrus, John Orazem et al.Neurology, May 01, 1998